K4 Elite
K4 Elite
Longevity & Cellular
FOXO4-DRI is a synthetic peptide built as a D-retro-inverso analogue of a segment of the human FOXO4 Forkhead transcription factor. In a D-retro-inverso design the residues are all D-amino acids and the sequence order is reversed relative to the parent L-peptide, an arrangement intended to preserve the spatial presentation of the side chains while making the molecule resistant to proteases. It was described by Baar and colleagues in Cell in 2017 as a tool for interrupting the interaction between FOXO4 and the tumour suppressor p53 inside senescent cells [1].
Cells that enter a senescent state stop dividing but remain metabolically active and secrete a characteristic mixture of cytokines, chemokines and proteases. The 2017 work reported that FOXO4 is elevated in senescent cells and forms nuclear foci together with p53, keeping p53 in the nucleus and away from the mitochondrial, apoptosis-promoting role it can otherwise play. A peptide that competes for that interface is predicted to release p53, allowing it to relocate and trigger cell-intrinsic apoptosis preferentially in cells that carry the senescent phenotype, while non-senescent cells are comparatively unaffected [1]. A 2025 structural study in Nature Communications mapped the interaction more precisely, identifying the intrinsically disordered transactivation domain of p53 as the region engaged by both FOXO4 and FOXO4-DRI [2].
Baar et al. reported that treatment of cultured human IMR90 fibroblasts reduced the fraction of senescence-associated beta-galactosidase positive cells while leaving proliferating controls largely intact. The same paper described experiments in three mouse settings: doxorubicin-induced chemotoxicity, the fast-ageing Xpg-deficient strain, and naturally aged animals, reporting changes in fur density, spontaneous activity and renal function markers in the treated groups [1]. These are rodent and cell-culture findings; the paper makes no claim about humans.
Subsequent groups have applied the peptide in narrower systems. A 2020 report in Aging described selective p53 nuclear exclusion and apoptosis in senescent Leydig cells and changes in the testicular microenvironment of naturally aged mice [3]. A 2021 study in Frontiers in Bioengineering and Biotechnology used serially expanded human chondrocytes and reported that treatment removed roughly half the cells in a late-passage, senescence-enriched population while producing no notable loss in an early-passage population, consistent with selectivity for the senescent fraction [4]. A 2025 report in Communications Biology examined keloid-derived fibroblasts and described apoptosis associated with nuclear exclusion of serine-15 phosphorylated p53 [5].
Two features of the molecule shape how it behaves in culture. The first is protease resistance: an all-D backbone is not cleaved by the endopeptidases that would rapidly degrade an equivalent L-peptide, so exposure in a cell-culture experiment is governed by uptake and by medium turnover rather than by proteolysis. The second is that the peptide carries cell-penetrating character, which means uptake is not receptor-mediated and is sensitive to serum content, cell density and incubation time. Studies in this area therefore usually include a non-senescent control population from the same donor or passage series, as the chondrocyte work did by comparing early-passage with late-passage cells from the same expansion [4], because a viability drop measured without that comparison cannot distinguish selective clearance from general cytotoxicity.
Reviews of the senolytics field place peptide-based FOXO4 antagonists alongside small molecules such as dasatinib plus quercetin and navitoclax, and note that clinical development to date has centred on the small molecules, with early-phase human trials in specific indications rather than in ageing as such [6]. Senescence is also heterogeneous: markers used to define a senescent cell in culture do not map cleanly onto tissue states, which complicates any claim that a compound clears senescent cells generally.
There are no published human clinical trials of FOXO4-DRI, and no human pharmacokinetic, safety or efficacy data exist. Independent groups have reproduced selective killing of senescent cells in defined cell types in vitro, but the systemic ageing results reported in 2017 have not been the subject of a large published independent replication. Nothing in the record establishes an effect on lifespan, healthspan, disease incidence or any clinical endpoint in people, and the assays used in these papers measure surrogate markers of senescence rather than clinical outcomes. Reported off-target effects, dose–response behaviour and tissue distribution in humans are unknown.
Format. Supplied as a lyophilised powder in a sealed vial. Peptide content is stated on the accompanying certificate of analysis; sequence-specific counter-ion and water content mean the vial mass and the net peptide mass are not identical.
Reconstitution. Long, partly hydrophobic sequences of this type are commonly dissolved in a small volume of a suitable solvent before dilution into aqueous buffer; consult the certificate of analysis for the solvent the manufacturer specifies. Add diluent slowly down the vial wall and swirl rather than shake. Concentrations can be worked out with the reconstitution calculator.
Storage. Store the sealed lyophilised vial at −20°C, protected from light and moisture, and allow it to reach room temperature before opening to avoid condensation. Reconstituted material is stored refrigerated and used within the working window recorded for the experiment; avoid repeated freeze–thaw cycles by preparing single-use aliquots.
Handling. Work aseptically, record lot number and reconstitution date, and treat all solutions as laboratory reagents. For in-vitro laboratory research only — not for human or veterinary use.